RELMADA THERAPEUTICS Reports Officer/Director Changes
Ticker: RLMD · Form: 8-K · Filed: Jan 3, 2024 · CIK: 1553643
| Field | Detail |
|---|---|
| Company | Relmada Therapeutics, Inc. (RLMD) |
| Form Type | 8-K |
| Filed Date | Jan 3, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: executive-changes, corporate-governance, compensatory-arrangements
TL;DR
**RELMADA just announced executive changes, watch for strategic shifts.**
AI Summary
RELMADA THERAPEUTICS, INC. filed an 8-K on January 3, 2024, to report a 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.' This filing indicates changes in key personnel and their compensation structures, which could impact the company's strategic direction and operational stability. Investors should note these changes as they may signal shifts in leadership and future performance, potentially affecting stock valuation.
Why It Matters
Changes in leadership can significantly influence a company's future strategy and operational execution, directly impacting its stock performance and investor confidence.
Risk Assessment
Risk Level: medium — Changes in leadership can introduce uncertainty regarding future company direction and stability, posing a moderate risk to investors.
Analyst Insight
Investors should monitor subsequent filings or company announcements for specific details on the personnel changes and their potential impact on the company's strategic direction and financial outlook. This filing is a precursor to more specific news.
Key Numbers
- $0.001 — par value per share (This is the stated par value for RELMADA's common stock.)
Key Players & Entities
- RELMADA THERAPEUTICS, INC. (company) — registrant
- January 3, 2024 (date) — date of earliest event reported
- Nevada (company) — state of incorporation for RELMADA THERAPEUTICS, INC.
- 001-39082 (company) — Commission File Number
- 45-5401931 (company) — IRS Employer Identification No.
- 2222 Ponce de Leon Blvd., Floor 3 Coral Gables, FL 33134 (company) — Address of principal executive offices
- (786) 629-1376 (company) — Registrant’s telephone number
- $0.001 (dollar_amount) — par value per share of common stock
Forward-Looking Statements
- RELMADA THERAPEUTICS, INC. will announce specific names of departing and appointed officers/directors in a subsequent filing or press release. (RELMADA THERAPEUTICS, INC.) — high confidence, target: Q1 2024
- The new compensatory arrangements will be detailed, potentially impacting future SG&A expenses. (RELMADA THERAPEUTICS, INC.) — medium confidence, target: Q1 2024
FAQ
What was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 3, 2024, as stated under 'Date of Report (Date of earliest event reported): January 3, 2024'.
What specific items are covered in this 8-K filing?
This 8-K filing covers 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers' as indicated in the 'ITEM INFORMATION' section.
What is the state of incorporation for RELMADA THERAPEUTICS, INC.?
RELMADA THERAPEUTICS, INC. is incorporated in Nevada, as specified in the filing under 'Nevada (State or other jurisdiction of incorporation)'.
What is the par value of RELMADA THERAPEUTICS, INC.'s common stock?
The common stock of RELMADA THERAPEUTICS, INC. has a par value of $0.001 per share, as stated under 'Common stock, $0.001 par value per'.
What is the business address of RELMADA THERAPEUTICS, INC.?
The business address of RELMADA THERAPEUTICS, INC. is 2222 Ponce de Leon Blvd., Floor 3, Coral Gables, FL 33134, according to the filing.
Filing Stats: 407 words · 2 min read · ~1 pages · Grade level 11.8 · Accepted 2024-01-03 17:00:26
Key Financial Figures
- $0.001 — nge on which registered Common stock, $0.001 par value per share RLMD The NASDAQ
Filing Documents
- ea191111-8k_relmada.htm (8-K) — 23KB
- 0001213900-24-000858.txt ( ) — 191KB
- rlmd-20240103.xsd (EX-101.SCH) — 3KB
- rlmd-20240103_lab.xml (EX-101.LAB) — 33KB
- rlmd-20240103_pre.xml (EX-101.PRE) — 22KB
- ea191111-8k_relmada_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 3, 2024 RELMADA THERAPEUTICS, INC. By: /s/ Sergio Traversa Name: Sergio Traversa Title: Chief Executive Officer 2